Novel Mithramycin Derivatives for Cancer Chemotherapy (2198)
- 技術優勢
- Key Advantages • Improved selectivity for betterefficacy and fewer off-target effects• Potential for less toxicity thanavailable chemotherapeutic agents currently in the clinic• Better pharmacological propertiesthan current chemotherapies in use today
- 詳細技術說明
- The University of Kentucky is seeking a partner to further develop and commercializevarious mithramycin SA derivatives that were synthesized from a mithramycinSA-producing mutant. The derivatives of particular interest are thosecontaining the dipeptides L-Phe and L-Trp, and provide the potential for moreefficacious and less toxic chemotherapeutic interventions for Ewing’s Sarcoma.
- *Abstract
-
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
